DK1230354T3 - Permanent amniocytcellelinje, frembringelse deraf og anvendelse deraf til frembringelse af genoverføringsvektorer - Google Patents

Permanent amniocytcellelinje, frembringelse deraf og anvendelse deraf til frembringelse af genoverføringsvektorer

Info

Publication number
DK1230354T3
DK1230354T3 DK00979539T DK00979539T DK1230354T3 DK 1230354 T3 DK1230354 T3 DK 1230354T3 DK 00979539 T DK00979539 T DK 00979539T DK 00979539 T DK00979539 T DK 00979539T DK 1230354 T3 DK1230354 T3 DK 1230354T3
Authority
DK
Denmark
Prior art keywords
die
generation
amniozyten
der
von
Prior art date
Application number
DK00979539T
Other languages
Danish (da)
English (en)
Inventor
Stefan Kochanek
Gudrun Schiedner
Original Assignee
Cevec Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals Gmbh filed Critical Cevec Pharmaceuticals Gmbh
Application granted granted Critical
Publication of DK1230354T3 publication Critical patent/DK1230354T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material
    • C12N2710/10352Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405Vectors comprising RGD peptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018Adenoviridae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
DK00979539T 1999-11-18 2000-11-07 Permanent amniocytcellelinje, frembringelse deraf og anvendelse deraf til frembringelse af genoverføringsvektorer DK1230354T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19955558A DE19955558C2 (de) 1999-11-18 1999-11-18 Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren

Publications (1)

Publication Number Publication Date
DK1230354T3 true DK1230354T3 (da) 2004-03-22

Family

ID=7929523

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00979539T DK1230354T3 (da) 1999-11-18 2000-11-07 Permanent amniocytcellelinje, frembringelse deraf og anvendelse deraf til frembringelse af genoverføringsvektorer

Country Status (16)

Country Link
EP (1) EP1230354B1 (zh)
JP (1) JP4456790B2 (zh)
CN (1) CN100412201C (zh)
AT (1) ATE257512T1 (zh)
AU (1) AU784003B2 (zh)
CA (1) CA2391591C (zh)
CZ (1) CZ300124B6 (zh)
DE (2) DE19955558C2 (zh)
DK (1) DK1230354T3 (zh)
ES (1) ES2211647T3 (zh)
HU (1) HU227440B1 (zh)
IL (2) IL149291A0 (zh)
PL (1) PL205966B1 (zh)
PT (1) PT1230354E (zh)
TR (1) TR200400402T4 (zh)
WO (1) WO2001036615A2 (zh)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528101A1 (en) * 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
AU2005214090B2 (en) 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
CN101155915B (zh) 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
DE102005054628A1 (de) * 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
FI2061803T4 (fi) 2006-08-28 2023-03-14 Process for the purification of fc-containing proteins
ES2532015T3 (es) 2008-11-03 2015-03-23 Crucell Holland B.V. Método para la producción de vectores adenovíricos
DE102009003439A1 (de) * 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie
AU2010305765B2 (en) 2009-10-15 2015-07-02 Crucell Holland B.V. Method for the purification of adenovirus particles
CN102575233B (zh) 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 从高细胞密度培养物纯化腺病毒的方法
WO2011098592A1 (en) 2010-02-15 2011-08-18 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
TW201211257A (en) 2010-08-16 2012-03-16 Cevec Pharmaceuticals Gmbh Permanent human cell line for influenza virus preparation
US9404090B2 (en) * 2011-11-24 2016-08-02 Viromed Co., Ltd. Adenovirus producing novel cell line and the use thereof
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CN104379733B (zh) 2012-03-12 2016-01-20 克鲁塞尔荷兰公司 具改变末端的重组腺病毒群
MY169352A (en) 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
EP2662451A1 (en) 2012-05-07 2013-11-13 Stefan Kochanek Nucleic acid construct and use of the same
EP2909228A1 (en) * 2012-10-19 2015-08-26 CEVEC Pharmaceuticals GmbH Production of a hcmv based vaccine in human amniocyte cell lines
EP2722337A1 (en) * 2012-10-19 2014-04-23 CEVEC Pharmaceuticals GmbH Production of a HCMV based vaccine in human amniocyte cell lines
MX361774B (es) 2013-04-25 2018-12-17 Janssen Vaccines & Prevention Bv Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados.
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
WO2015000856A1 (de) 2013-07-01 2015-01-08 Charité - Universitätsmedizin Berlin Immortalisierte humane chorionzelllinie sowie verfahren zur immortalisierung humaner chorionzellen
CN107075521B (zh) 2014-11-04 2021-06-08 扬森疫苗与预防公司 治疗性hpv16疫苗
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化された可溶性融合前rsv fポリペプチド
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
EA037295B1 (ru) 2015-08-20 2021-03-05 Янссен Вэксинс Энд Превеншн Б.В. Терапевтические вакцины против hpv18
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
AU2017259259B2 (en) 2016-05-02 2020-11-19 Bavarian Nordic A/S Therapeutic HPV vaccine combinations
RU2758238C2 (ru) 2016-05-12 2021-10-26 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
KR102111244B1 (ko) 2017-02-09 2020-05-15 얀센 백신스 앤드 프리벤션 비.브이. 이종 유전자의 발현을 위한 강력한 짧은 프로모터
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3681533A1 (en) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
WO2019086450A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
SG11202003398SA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus vectors and uses thereof
SG11202003290RA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus and uses thereof
US11142551B2 (en) 2017-10-31 2021-10-12 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
US20220273787A1 (en) 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CA3140234A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
AU2020342349A1 (en) 2019-09-02 2022-03-03 Biotest Ag Factor VIII protein with increased half-life
IL291852A (en) 2019-10-03 2022-06-01 Janssen Vaccines & Prevention Bv Adenovirus vectors and their use
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
EP4106798A1 (en) 2020-02-17 2022-12-28 Biotest AG Subcutaneous administration of factor viii
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
CN116406425A (zh) 2020-10-15 2023-07-07 豪夫迈·罗氏有限公司 用于va rna转录的核酸构建体
WO2022079082A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Nucleic acid constructs for simultaneous gene activation
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
WO2023227438A1 (en) 2022-05-23 2023-11-30 F. Hoffmann-La Roche Ag Raman-based method for the differentiation of aav particle serotype and aav particle loading status
WO2023232922A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024013239A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024056561A1 (en) 2022-09-12 2024-03-21 F. Hoffmann-La Roche Ag Method for separating full and empty aav particles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333425T5 (es) * 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica

Also Published As

Publication number Publication date
PT1230354E (pt) 2004-04-30
JP2003514526A (ja) 2003-04-22
ES2211647T3 (es) 2004-07-16
IL149291A0 (en) 2002-11-10
DE19955558A1 (de) 2001-06-07
TR200400402T4 (tr) 2004-03-22
PL205966B1 (pl) 2010-06-30
WO2001036615A3 (de) 2002-01-10
ATE257512T1 (de) 2004-01-15
JP4456790B2 (ja) 2010-04-28
CA2391591C (en) 2008-12-30
HUP0203387A3 (en) 2005-07-28
CN100412201C (zh) 2008-08-20
PL357495A1 (en) 2004-07-26
HUP0203387A2 (hu) 2002-12-28
CZ300124B6 (cs) 2009-02-18
DE50004995D1 (de) 2004-02-12
IL149291A (en) 2008-11-26
CA2391591A1 (en) 2001-05-25
HU227440B1 (en) 2011-06-28
AU1699001A (en) 2001-05-30
EP1230354A2 (de) 2002-08-14
EP1230354B1 (de) 2004-01-07
AU784003B2 (en) 2006-01-12
CZ20021709A3 (cs) 2002-08-14
WO2001036615A2 (de) 2001-05-25
DE19955558C2 (de) 2003-03-20
CN1433476A (zh) 2003-07-30

Similar Documents

Publication Publication Date Title
DK1230354T3 (da) Permanent amniocytcellelinje, frembringelse deraf og anvendelse deraf til frembringelse af genoverføringsvektorer
SE9900100D0 (sv) New compounds
MA26771A1 (fr) Benzoheterocycles et leur utilisation comme inhibiteurs de mek.
WO1998007830A3 (en) COMPLETE GENOME SEQUENCE OF THE METHANOGENIC ARCHAEON, $i(METHANOCOCCUS JANNASCHII)
AU2001282008A1 (en) Method for accessing a cellular communication network
DK1210406T3 (da) Flokkulering af cellemateriale
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
IT1264516B1 (it) Cellule dendritiche immortalizzate
DK1204659T3 (da) Serotonerge benzofuraner
TR199901386T2 (en) �midazopiridazinler.
ATE280169T1 (de) Serotonerge benzothiophene
WO2001059138A3 (en) Plant internal ribosome entry segment
ATE57917T1 (de) Hydroxipyrazol-derivate- verfahren zu ihrer herstellung und ihre verwendung gegen mikroorganismen.
DE60031369D1 (de) Replikation -defektive baculoviren expressionssystem
WO2000061729A3 (en) Regulation of the expression of transcriptional repressor genes using nucleic acid molecules
TR200100142T2 (tr) R-(+)-6-Karboksamido-3-N-Metilamino-1,2,3,4- tetrahidrokarbazol üretimi için işlem.
TR199700513A2 (xx) Reaktif aluminyumftalosiyanin boyar maddeleri, �retilmelerine mahsus usul ve bunlar�n kullan�lmas�.
BR0014489B1 (pt) processo de produÇço de adenovÍrus, e, kit.
IT1311817B1 (it) Fermentatore con dispositivo per il rimontaggio del mosto.
BR0207647B1 (pt) processo de regulação de uma célula de eletrólise.
WO2000066787A3 (en) Growth hormone-regulatable liver genes and proteins, and uses thereof
FR2794541B1 (fr) Dispositif pour realiser une economie d'energie, pourvu d'une intelligence artificielle
Adamski Engineers of the Future: PEs or PhDs\= Bidders or Proposers
BG104401A (en) Chloroacetamide mixtures with suppressed precipitation
HU908102D0 (en) Process for stereoselective production of 1-bromine-3-chlorine,1,2-diaryl-2-propanoles in given case and their transformation into azolyl-methyl-oxiranes